Pathologic Complete Response and Survival in Rectal Cancer A Systematic Review and Meta-Analysis Pathologic Complete Response and Survival in Rectal Cancer Pathologic Complete Response and Survival in Rectal Cancer
Kavin Sugumar, Jessica Jin Lie, Chee-Chee Stucky, Yu-Hui Chang, Justin Brady, Nabil Wasif, Mohamad Bassam Sonbol, David Etzioni, Harvey Mamon, Tanios Bekaii-Saab, Zhi Ven Fong
Abstract
Clinical end points are used to assess the effectiveness of novel cancer therapies.1 Overall survival (OS) is considered the reference standard end point for estimating long-term efficacy in oncologic drug development,2 but measuring OS can be expensive and time-consuming and lacks information on quality of life and treatment failure.1 In an attempt to solve these problems, investigators have developed surrogate end points (SEPs) of long-term outcomes for various cancer types, which have been increasingly used during the past decade.3 In Japan, nearly two-thirds of all oncologic drug approvals
§ The Valyu brief
Reading the full paper and taking notes. This takes a few seconds…
§ Ask this paper
Ask a question about this paper
Valyu reads the full text and answers from what the paper actually says.
Searching the other archives…